SITUNAYAKE RD, KITAS G. Dyslipidaemia and rheumatoid arthritis. Annals of the Rheumatic Diseases. 1997;56(6):341–2.
2.
Gabriel SE. Heart disease and rheumatoid arthritis: understanding the risks. Annals of the Rheumatic Diseases. 2010;69:i61–4.
3.
Goodson NJ, Symmons DPM, Scott DGI, Bunn D, Lunt M, Silman AJ. Baseline levels of c‐reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis : A ten‐year followup study of a primary care–based inception cohort. Arthritis & Rheumatism. 2005;52(8):2293–9.
4.
Aubry MC, Maradit-Kremers H, Reinalda MS. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol. 2007;34:937–42.
5.
Doornum S, B K, C B. Mortality rates following a first acute cardiovascular event: a comparison between rheumatoid arthritis patients and the general population. Arthritis Rheum. 2005;52:702.
6.
Douglas KMJ, Pace AV, Treharne GJ, Saratzis A, Nightingale P, Erb N, et al. Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome. Annals of the Rheumatic Diseases. 2006;65(3):348–53.
7.
Banks MJ, Pace A, Kitas GD. Acute coronary syndromes present atypically and recur more frequently in rheumatoid arthritis than matched controls [abstract. Arthritis Rheum. 2001;44(Suppl.):53.
8.
Peters MJL, Symmons DPM, McCarey D, Dijkmans BAC, Nicola P, Kvien TK, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Annals of the Rheumatic Diseases. 2010;69(2):325–31.
9.
Goodson N. Coronary artery disease and rheumatoid arthritis. Current Opinion in Rheumatology. 2002;14(2):115–20.
10.
Fischer LM, Schlienger RG, Matter C, Jick H, Meier CR. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of First-Time acute myocardial infarction. The American Journal of Cardiology. 2004;93(2):198–200.
11.
Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular Morbidity and Mortality in Women Diagnosed With Rheumatoid Arthritis. Circulation. 2003;107(9):1303–7.
12.
Hallajzadeh J, Safiri S, Mansournia MA, Khoramdad M, Izadi N, Almasi-Hashiani A, et al. Metabolic syndrome and its components among rheumatoid arthritis patients: A comprehensive updated systematic review and meta-analysis. PLOS ONE. 12(3):e0170361.
13.
Mantel-Teeuwisse AK, Kloosterman JME, Maitland-van der Zee AH, Klungel OH, Porsius AJ, de Boer A. Drug-Induced Lipid Changes. Drug Safety. 2001;24(6):443–56.
14.
McMahon M, Grossman J, FitzGerald J, Dahlin‐Lee E, Wallace DJ, Thong BY, et al. Proinflammatory high‐density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis & Rheumatism. 2006;54(8):2541–9.
15.
Choy E, Ganeshalingam K, Semb AG, Szekanecz Z, Nurmohamed M. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology. 2014;53(12):2143–54.
16.
Aletaha D, Smolen JS. Evaluation and outcomes of patients with rheumatoid arthritis. Rheumatology. 2011. p. 941-954.e1.
17.
Myasoedova E, Chandran A, Ilhan B, Major BT, Michet CJ, Matteson EL, et al. The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease. Annals of the Rheumatic Diseases. 2016;75(3):560–5.
18.
Pincus T, Yazici Y, Bergman M. Development of a Multidimensional Health Assessment Questionnaire (MDHAQ) for the infrastructure of standard clinical care. Clin Exp Rheumatol. 2005;23.
19.
Falgrone G, Zerkak D, Bauer C. How to define a Minimal Clinically Individual State (MCIS) with pain VAS in daily practice for patients suffering from musculoskeletal disorders. Clin Exp Rheumatol. 2005;23:235–8.
20.
Leeb BF. The patient’s perspective and rheumatoid arthritis disease activity indexes. Rheumatology. 44(3):360–5.
21.
Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. Circulation. 2014;129(25_suppl_2).
22.
Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. The Lancet. 2005;365(9468):1415–28.
23.
Ward MM. Clinical and laboratory measures. 2004.
24.
Welsing PMJ, Van Gestel AM, Swinkels HL, Kiemeney LALM, Van Riel PLCM. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis & Rheumatism. 2001;44(9):2009–17.
25.
Bruce B, Fries JF. Health and Quality of Life Outcomes. 2003;1(1):20.
26.
Aletaha D, Smolen JS. Outcome Measurement in Rheumatoid Arthritis: Disease Activity. Rheumatoid Arthritis. 2009. p. 225–30.
27.
Bartoloni E, Alunno A, Bistoni O, Gerli R. How early is the atherosclerotic risk in rheumatoid arthritis? Autoimmunity Reviews. 2010;9(10):701–7.
28.
Arend WP. Physiology of cytokine pathways in rheumatoid arthritis. Arthritis & Rheumatism. 2001;45(1):101–6.
29.
Kaplan MJ. Cardiovascular disease in rheumatoid arthritis. Current Opinion in Rheumatology. 2006;18(3):289–97.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
